Tabula Rasa Healthcare Inc. (TRHC)
(Delayed Data from NSDQ)
$55.29 USD
+2.12 (3.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.17 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$55.29 USD
+2.12 (3.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.17 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Grab 5 Top Stocks With Strong Earnings Beat Prospects
by Sanghamitra Saha
Invest in top-ranked stocks that are likely to beat their earnings estimates in the upcoming releases.
Is Tabula Rasa Healthcare (TRHC) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (TRHC) Outperforming Other Medical Stocks This Year?
MDRX or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MDRX vs. TRHC: Which Stock Is the Better Value Option?
Tabula Rasa Healthcare (TRHC) Beats Q3 Earnings Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 22.22% and -1.46%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Tabula Rasa Healthcare (TRHC) Q3 Earnings Expected to Decline
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology
Stocks & ETF to Invest in Healthcare Robotics and Innovation
by Neena Mishra
HTEC is poised to benefit from rapid advances in health-care technology.
Tabula Rasa HealthCare, Simpson Manufacturing, Verizon Communications, Coca-Cola and Jack in the Box highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tabula Rasa HealthCare, Simpson Manufacturing, Verizon Communications, Coca-Cola and Jack in the Box highlighted as Zacks Bull and Bear of the Day
Bull of the Day: Tabula Rasa Healthcare (TRHC)
by Kevin Cook
Medication safety is top priority for care providers and this small cap IT ninja is building the network's intelligence
Tabula Rasa Healthcare (TRHC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 600.00% and 8.69%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Tabula Rasa Healthcare (TRHC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NXGN or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
NXGN vs. TRHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
NXGN or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NXGN vs. TRHC: Which Stock Is the Better Value Option?
Tabula Rasa Healthcare (TRHC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of 66.67% and 2.90%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
2 Healthcare Innovators To Buy Now
by Kevin Cook
My innovation radar is hot on the trail of genetic diagnostics and advanced medical records IT.
Tabula Rasa, Tesla, Roku and Netflix as Zacks Bull and Bear of the Day
by Zacks Equity Research
Tabula Rasa, Tesla, Roku and Netflix as Zacks Bull and Bear of the Day
Bull of the Day: Tabula Rasa HealthCare (TRHC)
by Kevin Cook
Exploding medical data is being harnessed by this $1.2 billion IT integrator and patient safety innovator
Earnings Preview: Tabula Rasa Healthcare (TRHC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CERN vs. TRHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
CERN vs. TRHC: Which Stock Is the Better Value Option?
CERN or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CERN vs. TRHC: Which Stock Is the Better Value Option?
Tabula Rasa Healthcare (TRHC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CPSI vs. TRHC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CPSI vs. TRHC: Which Stock Is the Better Value Option?
CPSI or TRHC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CPSI vs. TRHC: Which Stock Is the Better Value Option?
Tabula Rasa Healthcare (TRHC) Lags Q3 Earnings Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -3.70% and 2.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?